DCLK2(DCAMKL2)
Sign in to save this workspaceUniProt Q8N568 · PDB · AlphaFold · Substrate: ZIPtide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ceritinib | 77.7% | 22.3% | 95.44 | 0.618 |
| 2 | Lorlatinib | 69.7% | 30.3% | 97.24 | 0.694 |
| 3 | Crizotinib | 65.4% | 34.6% | 91.39 | 0.581 |
| 4 | Brigatinib | 60.0% | 40.0% | 82.96 | 0.513 |
| 5 | Baricitinib | 54.6% | 45.4% | 97.99 | 0.616 |
| 6 | Ruxolitinib | 44.4% | 55.6% | 98.25 | 0.592 |
| 7 | Abemaciclib | 34.5% | 65.5% | 91.48 | 0.563 |
| 8 | Fedratinib | 33.6% | 66.4% | 96.21 | 0.576 |
| 9 | Pemigatinib | 30.1% | 69.9% | 98.23 | 0.718 |
| 10 | Upadacitinib | 28.0% | 72.0% | 97.98 | 0.663 |
| 11 | Dabrafenib | 21.7% | 78.3% | 94.74 | 0.633 |
| 12 | Sunitinib | 19.4% | 80.6% | 91.73 | 0.524 |
| 13 | Neratinib | 17.2% | 82.8% | 93.18 | 0.597 |
| 14 | Palbociclib | 17.1% | 82.9% | 98.75 | 0.673 |
| 15 | Axitinib | 14.8% | 85.2% | 93.23 | 0.688 |
| 16 | Midostaurin | 14.4% | 85.6% | 78.64 | 0.500 |
| 17 | Repotrectinib | 13.7% | 86.3% | 84.21 | 0.608 |
| 18 | Gilteritinib | 12.7% | 87.3% | 88.97 | 0.506 |
| 19 | Ponatinib | 10.6% | 89.4% | 78.23 | 0.534 |
| 20 | Defactinib | 10.2% | 89.8% | 92.68 | 0.450 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.54
- Epithelial log2(TPM+1): 1.01
- Fold change: 1.52
- Status: Upregulated
Selectivity landscape vs inhibition on DCLK2
Each point is one of the 92 approved drugs; color = inhibition % on DCLK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…